Study summary

Zipalertinib shrank exon 20 insertion tumors in about a third of patients

REZILIENT1 trial (zipalertinib) · 244 people, phase 1/2 · Published July 2025, Journal of Clinical Oncology

35.2%of tumors shrank

What was tested

Zipalertinib, an EGFR pill designed for the less common exon 20 insertion mutations, in people already treated with chemotherapy, with or without amivantamab. No comparison group.

What they found

What it means

Adds a pill option for exon 20 insertions; a first-line trial with chemotherapy is under way.

J Clin Oncol, via PubMed ↗ Trial record NCT04036682 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.